Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Scott W. Lowe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5284-9650; OpenAlex author ID A5025451142, A5158608406; NIH RePORTER profile ID 1928317. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 4)
Trials
0
Grants
2
Labs led
1
Collaborators
74
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 4 papers, 1 grant · 2025: 2 papers · 2026: 2 papers, 1 grant

Papers 16

  1. Molecular landscape of anaplastic transformation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.70136↗
  2. GATA4 loss promotes mutant Kras -driven pancreatic ductal adenocarcinoma in the absence of canonical precursor lesions Co-author DOI 10.64898/2026.05.22.724502↗
  3. SMAD4 induces opposite effects on metastatic growth from pancreatic tumors depending on the organ of residence. Last author DOI 10.1038/s43018-025-01047-5↗
  4. A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic D… Last author DOI 10.1158/2159-8290.cd-24-1425↗
  5. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  6. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  7. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0177↗
  8. uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence. Co-author DOI 10.2967/jnumed.124.268278↗
  9. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance. Co-author DOI 10.1038/s43018-023-00553-8↗
  10. Hypoxia Potentiates the Inflammatory Fibroblast Phenotype Promoted by Pancreatic Cancer Cell-Derived Cytokines. Co-author DOI 10.1158/0008-5472.can-22-2316↗
  11. MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-20-1826↗
  12. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.05.010↗
  13. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. Co-author DOI 10.1084/jem.20192389↗
  14. Evolutionary Dynamics of Non-Coding Regions in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.1101/2020.09.11.294389↗
  15. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Last author DOI 10.1016/j.cell.2014.01.066↗
  16. A modular and flexible ESC-based mouse model of pancreatic cancer. Last author DOI 10.1101/gad.232082.113↗

Grants 2

  1. Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis R01CA283378↗
  2. Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies R01CA233944↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dana Pe'er · 1 shared paper, 1 shared grant, 2025–2026 · strength 1.45
  2. Christine A. Iacobuzio–Donahue · 4 shared papers, 2020–2026 · strength 0.61
  3. Kaloyan M. Tsanov · 3 shared papers, 2023–2026 · strength 0.61
  4. Akimasa Hayashi · 2 shared papers, 2020–2026 · strength 0.32
  5. Eileen Mary O'Reilly · 2 shared papers, 2020–2026 · strength 0.32
  6. Timour Baslan · 2 shared papers, 2022–2025 · strength 0.29
  7. John P. Morris · 4 shared papers, 2014–2023 · strength 0.28
  8. Francesc Madriles Soriano · 1 shared paper, 2026 · strength 0.24
  9. Iréne Esposito · 1 shared paper, 2026 · strength 0.24
  10. Juan Iovanna · 1 shared paper, 2026 · strength 0.24
  11. Mónica P. de Andrés · 1 shared paper, 2026 · strength 0.24
  12. Paola Martinelli · 1 shared paper, 2026 · strength 0.24
  13. Francisco X. Real · 1 shared paper, 2026 · strength 0.24
  14. Takahiro Shibayama · 1 shared paper, 2026 · strength 0.23
  15. Yoshihiro Sakamoto · 1 shared paper, 2026 · strength 0.23
  16. Wungki Park · 1 shared paper, 2026 · strength 0.23
  17. Junji Shibahara · 1 shared paper, 2026 · strength 0.23
  18. Edwin Charles Pratt · 1 shared paper, 2024 · strength 0.22
  19. Jason Stuart Lewis · 1 shared paper, 2024 · strength 0.22
  20. Simon Schwörer · 1 shared paper, 2023 · strength 0.19
  21. Craig B Thompson · 1 shared paper, 2023 · strength 0.19
  22. Caroline Broderick · 1 shared paper, 2025 · strength 0.19
  23. Mallika Singh · 1 shared paper, 2025 · strength 0.19
  24. Geulah Yevgeniya Livshits · 1 shared paper, 2025 · strength 0.19
  25. Joan Massagué Solé · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.